

07-24-02 10E7

(AP) 16 44 6 1 101P2

Patent Docket P1101P2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Avi J. Ashkenazi et al.

Serial No.: 09/396,710

Filed: September 15, 1999

For:

APO-2 RECEPTOR ANTIBODIES

Group Art Unit: 1644

Examiner: D. Saunders.

CERTIFICATE OF EXPRESS MAILING EXPRESS MAIL LABEL NO. <u>EV 073727942 US</u>

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated below and is addressed to "Assistant Commissioner of Patents, Washington, D.C. 20231.

July 22, 2002

Diane L. Marschang

TRANSMITTAL LETTER

Assistant Commissioner of Patents Washington, D.C. 20231

Sir:

Transmitted herewith are the following documents:

- 1. Supplemental Information Disclosure Statement
- 2. Form PTO-1449 with 1 reference
- 3. Return postcard.

In the event any additional fees are due in connection with the filing of these documents, the Commissioner is authorized to charge such fees to our Deposit Account No. 07-0630.

Respectfully submitted,

GENENTECH, INC.

Date: July <u>22</u>, 2002

By: __

Diane L. Marschang

Reg. No. 35,600

Telephone No. (650) 225-5416

09157
PATENT TRADEMARK OFFICE

#116968



Patent Docket P1101P2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Avi J. Ashkenazi et al.

Serial No.: 09/396,710

Filed: September 15, 1999

For: APO-2 RECEPTOR ANTIBODIES

Group Art Unit: 1646

Examiner: C. Kaufman

CERTIFICATE OF MAILING EXPRESS MAIL LABEL NO.: EV 073727942 US

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated below and is addressed to "Assistant Commissioner of Patents Washington, D.C. 20231.

July <u>22</u>, 2002

Diane L. Marschang

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner of Patents Washington, D.C. 20231

Sir:

Applicants submit herewith patents, publications or other information (attached hereto and listed on the attached revised Form PTO-1449) of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR §1.56.

This Information Disclosure Statement is filed in accordance with the provisions of:

☐ 37 CFR §1.97(b)

- within three months of the filing date of the application other than a continued prosecution application under 37 CFR §1.53(d); or
- within three months of the date of entry of the national stage of a PCT application as set forth in 37 CFR§1.491, or
- before the mailing of the first Office action on the merits; or
- before the mailing of the first Office action after the filing of a request for a continued examination under 37 CFR §1.114.


[X] 37 CFR §1.97(c)

• by the applicant after the period specified in 37 CFR §1.97(b), but prior to the mailing date of any of a final action under 37 CFR §1.113, or a notice of allowance under 37 CFR §1.311, or an action that otherwise closes prosecution in the application, and is accompanied by either the fee set forth in 37 CFR §1.17(p) or a statement as specified in 37 CFR §1.97(e), as checked below.

07/25/2002 EAREGAY1 00000093 070530 09395710

01 FC:126

160.00 CH



JUL 2 9 2002 TECH CENTER 1600/2900



[X]The U.S. Patent and Trademark Office is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$180.00 to cover the cost of this Information Disclosure Statement under 37 CFR §1.17(p). Any deficiency or overpayment should be charged or credited to this deposit account.

A list of the patent(s) or publication(s) is set forth on the attached revised Form PTO-1449 (Modified). A copy of the item on PTO-1449 is supplied herewith. Applicants wish to advise that the cited patent on Form-1449 appears to be the counterpart application of PCT, WO 99/09165, previously cited by Applicants.

In accordance with 37 CFR §1.97(g), the filing of this information disclosure statement shall not be construed as a representation that a search has been made.

In accordance with 37 CFR §1.97(h), the filing of this information disclosure statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b).

In the event that the Office determines a fee to be due where none is specifically authorized in this paper, the U.S. Patent and Trademark Office is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$180.00 to cover the cost of this Information Disclosure Statement under 37 CFR §1.17(p).

Respectfully submitted,

GENENTECH, INC.

Diane L. Marschang

Reg. No. 35,600

Telephone No. (650) 225-5416

Diane L. Marsche

Date: July 22, 2002

Serial No.: 09/396,710

PATENT TRADEMARK OFFICE